A5063672693- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Adenosine and Purinergic Signaling
- Immune cells in cancer
- Chemokine receptors and signaling
- Adolescent and Pediatric Healthcare
- interferon and immune responses
- Monoclonal and Polyclonal Antibodies Research
- Atherosclerosis and Cardiovascular Diseases
- Bone Metabolism and Diseases
- Cytokine Signaling Pathways and Interactions
- CAR-T cell therapy research
- Immune Response and Inflammation
- Nanoplatforms for cancer theranostics
- Toxin Mechanisms and Immunotoxins
- Single-cell and spatial transcriptomics
- Cancer Cells and Metastasis
- Medicinal Plant Pharmacodynamics Research
- Reproductive System and Pregnancy
- Ferroptosis and cancer prognosis
- Cancer-related molecular mechanisms research
- NF-κB Signaling Pathways
- Photodynamic Therapy Research Studies
Institut de Recherche en Cancérologie de Montpellier
2017-2025
Immunité et Cancer
2022-2025
Université de Montpellier
2021-2025
Inserm
2011-2025
École Polytechnique Fédérale de Lausanne
2015-2022
Swiss Cancer Center Léman
2020
Centre Léon Bérard
2010-2018
Université Claude Bernard Lyon 1
2011-2018
Centre de Recherche en Cancérologie de Lyon
2010-2018
Centre National de la Recherche Scientifique
2012-2018
A bona fide portrayal of tumor growth Bone has a well-established role in advanced cancer. It provides supportive microenvironment for the metastatic cells that escape primary tumor, which ultimately leads to loss bone mass. Engblom et al. show may also contribute early-stage tumorigenesis through mechanism an increase mass (see Perspective by Zhang and Lyden). In mouse models lung adenocarcinoma, remotely activated bone-resident called osteoblasts, have bone-building function. The...
Abstract Infiltration and dysfunction of immune cells have been documented in many types cancers. We previously reported that plasmacytoid dendritic (pDC) within primary breast tumors correlate with an unfavorable prognosis for patients. The role pDC cancer remains unclear but they shown to mediate tolerance other pathophysiologic contexts. postulated may interfere antitumor response favor cancer. present study was designed decipher the mechanistic basis deleterious impact on clinical...
Abstract Neutrophils are an essential part of the innate immune system. To study their importance, experimental studies often aim to deplete these cells, generally by injecting anti-Ly6G or anti-Gr1 antibodies. However, approaches only partially effective, transient lack specificity. Here we report that neutrophils remaining after treatment newly derived from bone marrow, instead depletion escapees. Mechanistically, generated, circulating have lower Ly6G membrane expression, and consequently...
Understanding the immune compartment of tumors facilitates development revolutionary new therapies. We used a Kras(G12D)-driven mouse model lung cancer to establish an signature and identified contribution Gr1+ neutrophils disease progression. Depletion experiments showed that cells (1) favor tumor growth, (2) reduce T cell homing prevent successful anti-PD1 immunotherapy, (3) alter angiogenesis, leading hypoxia sustained Snail expression in cells. In turn, accelerated progression increased...
In ovarian cancer, the immune system fails to eradicate established tumors partly due induction of tolerance within tumor microenvironment. this study, we investigated contribution plasmacytoid dendritic cells (pDC) in establishment a cohort 44 cancer patients. and malignant ascites, CD4(+)CD123(+)BDCA2(+) pDC were most abundant cell subset; however, they profoundly depleted peripheral blood. The presence primary but not was an independent prognostic factor associated with early relapse....
Abstract Human breast tumors are infiltrated by memory CD4+ T cells along with increased numbers of regulatory (Treg) and plasmacytoid dendritic (pDC) that facilitate immune escape correlate poor prognosis. Here, we report inducible costimulatory molecule (ICOS), a cell the CTLA4/PD1/CD28 family, is expressed mostly tumor-associated Treg in primary tumors. A large proportion these ICOS+ were Ki67+ this evident proliferative expansion was found to rely on interactions pDC. Indeed, highly...
Abstract In breast carcinomas, patient survival seems to be negatively affected by the recruitment of regulatory T cells (Treg) within lymphoid aggregates CCL22. However, mechanisms underpinning this process, which may broader significance in solid tumors, have yet described. study, we determined how CCL22 production is controlled tumor cells. human carcinoma cell lines, was secreted at low basal levels that were strongly increased response inflammatory signals [TNF-α, IFN-γ, and interleukin...
Abstract The production of CD73-derived adenosine (Ado) by Tregs has been proposed as a resistance mechanism to anti-PD-1 therapy in murine tumor models. We reported that human express the ectonucleotidase CD39, which generates AMP from ATP, but do not AMPase CD73. In contrast, CD73 defined subset effector CD4+ T cells (Teffs) enriched polyfunctional Th1.17 characterized expression CXCR3, CCR6, and MDR1, IL17A/IFNγ/IL22/GM-CSF. CD39+ selectively targeted CD73+ Teffs through cooperative...
Regulatory T cells (Tregs) and plasmacytoid dendritic (pDCs) that infiltrate primary breast tumors impair patient survival. The ICOS-mediated interaction between tumor-infiltrating CD4+ pDCs leads to the amplification of Tregs interleukin-10 secretion. Importantly, ICOS+ cell infiltration correlates with adverse prognosis, identifying ICOS as a new target for cancer immunotherapy.
Background Colorectal cancer (CRC) is the third most common type and one of leading causes cancer-related death worldwide. The treatment advanced metastatic CRC relies on classical chemotherapy combinations (5-fluorouracil, oxaliplatin or irinotecan). However, their use limited by emergence resistance mechanisms, including to oxaliplatin. In this context, we recently showed that combination ataxia telangiectasia Rad3-related protein inhibition (VE-822) synergistic may have a potential...
Lung cancer is the leading cause of death by in world and finding new targets a major medical need to tackle this disease. Here, upon proteomic analysis identify common players oncogenic EGFR- KRAS-driven lung adenocarcinoma mouse models, we uncovered largely unknown protein cancer, flavin-containing monooxygenase 4 (FMO4), whose expression was increased tumors compared with adjacent tissue. FMO4 strongly also samples from patients healthy lung, its level inversely correlated overall...
The accumulation of plasmacytoid dendritic cells (pDCs) within breast carcinoma lesions is associated with a poor clinical outcome. We demonstrated that the deleterious impact tumor-associated pDCs (TApDCs) due to their impaired capacity produce Type I interferon, which in turn potentiates ability sustain proliferation immunosuppressive regulatory T cells.
Immune-based anti-cancer strategies combined with radiation therapy (RT) are actively being investigated but many questions remain, such as the ideal treatment scheme and whether a potent immune response can be generated both locally systemically. In this context, tumour-associated tertiary lymphoid structures (TLS) have become subject of research. While TLS present in several types cancer strong similarities, they especially relevant Medullary Breast Cancer (MBC). This suggests that MBC...
Activin-A, a transforming growth factor β family member, is secreted by many cancer types and often associated with poor disease prognosis. Previous studies have shown that Activin-A expression can promote progression reduce the intratumoral frequency of cytotoxic T cells. However, underlying mechanisms significance for therapies are unclear.We analyzed encoding gene INHBA in melanoma patients influence its gain- or loss-of-function on immune infiltration BRAF-driven YUMM3.3 iBIP2 mouse...
Triple-negative breast cancer (TNBC) has poorer outcomes than other cancers (BC), including HER2
Regulatory T cells (Treg) have been reported of poor prognosis for overall survival in primary breast tumors (BT). As CCL22 plays a major role Treg recruitment within BT we deciphered the mechanisms involved production by epithelial tumor and propose herein their innate immune recognition this production.
NSCLC is the leading cause of cancer mortality. Recent retrospective clinical analyses suggest that blocking receptor activator NF-κB (RANK) signaling pathway inhibits growth and might represent a new treatment strategy.Receptor gene ligand (RANKL) expression in human lung adenocarcinoma was interrogated from publicly available data sets. Several genetically engineered mouse models were used to evaluate efficacy RANK-Fc block RANKL, with primary tumor measured longitudinally using...
Summary Neutrophils orchestrate the innate immune response against microorganisms and are increasingly recognized to modulate cancer development in primary tumors metastases. To address their function vivo , different approaches used, most common ones relying on antibody-mediated neutrophil depletion. By comparing effects of two widely used antibodies, we demonstrate a strong efficacy but lack specificity for anti-Gr1. In contrast, anti-Ly6G lacks neutrophil-depletion capacity C57BL/6 mice,...
Malignant pleural mesothelioma (MPM) is a deadly disease with limited treatment options. Approaches to enhance patient immunity against MPM have been tested but shown variable results. Previously, we demonstrated interesting vascular modulating properties of low-dose photodynamic therapy (L-PDT) on MPM. Here, hypothesized that L-PDT modulation could favour immune cell extravasation in and improve tumour control combination checkpoint inhibitors.First, assessed the impact endothelial...
// Svenja Groeneveld 1 , Julien Faget Nadine Zangger 1, 2 and Etienne Meylan Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Switzerland Bioinformatics Core Facility, Bioinformatics, Correspondence to: Meylan, email: etienne.meylan@epfl.ch Keywords: Snail; Dlk1-Dio3 locus; lung adenocarcinoma; microenvironment; miRNA Received: March 09, 2018 Accepted: July 31, Published: August 17, 2018...